no image available Dickens & Co. "Beating the Odds: New Hope for High-Risk Myeloma Patients" "Pioneering Research Explores the Potential of Bortezomib in Combining Reduced Intensity Conditioning with Post-Transplant Immunoapheresis for Optimal Outcomes" Price: 21.00€